Adverum Biotechnologies, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Laurent Fischer
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 800 Saginaw Drive Redwood City CA United States of America 94063
- IPO Date
- Jul 31, 2014
- CIK
- 0001501756
- Website
- adverum.com
- Similar Companies
- Business
- Adverum Biotechnologies, Inc. functions as a clinical-stage enterprise focused on advancing gene therapies for addressing severe ocular and less common conditions. Its primary investigational therapy, ixoberogene soroparvovec (Ixo-vec), formerly ADVM-022, is designed as a singular intravitreal gene therapy for chronic retinal disorders including wet age-related macular degeneration and diabetic macular edema, aiming for a durable treatment effect. The company's pipeline also includes programs for blue-cone monochromacy and other retinal conditions. Adverum holds various licensing and partnership agreements with entities such as the University of California, GenSight Biologics, Lexeo Therapeutics, and Virovek, Inc. Significantly, Eli Lilly and Company has declared its intention to acquire Adverum, with the transaction anticipated to close in the fourth quarter of 2025, poised to further Ixo-vec's development, currently progressing through Phase 3 clinical trials. Established in 2006 as Avalanche Biotechnologies, Inc., the company adopted the Adverum Biotechnologies, Inc. name in May 2016 and is headquartered in Redwood City, California.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Consensus Target Price from Analysts
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
Shareholder Alert: The Ademi Firm investigates whether Adverum Biotechnologies, Inc. is obtaining a Fair Price for its Public Shareholders
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. is Fair to Shareholders
Lilly to Acquire Adverum Biotechnologies
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM